Use of Recombinant Factor VII as a Prophylactic Therapy for Adolescent Females With Heavy Menstrual Bleeding

Minia University Hospital

Status: Completed

Conditions: Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention

Treatments: Drug: Proph7

Study type: Observational

Funder types: Other

Identifiers

NCT06258980

MiniaUH

Details and patient eligibility

About

the study is conducted on adolescent females proved to be Glanzmanns Thrombaesthenia with heavy menstrual bleeding by the use of 3 doses of recombinant factor VII in the first day of their cycles. bleeding profile and quality of life were assessed before and 1year after this regular recombinant factor VII administration.

Enrollment: 3 patients

Sex: Female

Ages: 12 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adolescent females proved to be Glanzmanns Thrombaesthenia heavy menstrual bleeding no improvment by platelet transfusion or antifibrinolytic therapy

Exclusion criteria

chronic systemic disease previous allergic reaction to recombinant FVII

Trial design

3 participants in 1 patient group

heavily menstruating females with glanzmannns Thrombaesthenia

Treatment:

Drug: Proph7